Increase in distant stage breast cancer incidence rates in us women aged 25-49 years, 2000-2011: The stage migration hypothesis

Journal of Cancer Epidemiology

Volumn 2015, Issue , 2015, Pages

  Polednak, Anthony P ^a  

^a Private Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; DISTANT METASTASIS; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; SURVIVAL RATE; UNITED STATES;

EID: 84921341294     PISSN: 16878558     EISSN: 16878566     Source Type: Journal    
DOI: 10.1155/2015/710106     Document Type: Article

References (33)

1. R. H. Johnson, F. L. Chien, and A. Bleyer, and quot;Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009, and " JAMA-Journal of the American Medical Association, vol. 309, no. 8, pp. 800-805, 2013.
2. D. Grady, and quot;Study sees more breast cancer at young age, and " New York Times, 2013, http://www.nytimes.com/2013/02/27/health/ advanced-breast-cancer-may-be-rising-among-young-womenstudy-finds.htmlr=0.
3. G. Hortobágyi and P. Conte, and quot;Interpreting cancer biology: refining our therapeutic algorithm in breast cancer, and " The Oncologist, vol. 18, no. 4, pp. e8-e10, 2013.
4. R. H. Johnson, F. L. Chien, and A. Bleyer, and quot;Incidence rate of breast cancer in young women-reply, and " The Journal of the American Medical Association, vol. 309, no. 23, pp. 2435-2436, 2013.
5. N. Howlader, A. K. Noone, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975-2011, National Cancer Institute, Bethesda, Md, USA, 2014.
6. A. R. Feinstein, D. M. Sosin, and C. K. Wells, and quot;TheWill Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer, and " The New England Journal ofMedicine, vol. 312, no. 25, pp. 1604-1608, 1985.
7. National Cancer Institute. Surveillance Research Program, and quot;SEER∗Stat software version 8. 1. 5. SEER Program Database: Incidence-SEER 18 Regs Research Data. Nov 2013 submission (2000-2011), and " 2014.
8. B. K. Edwards, A.-M. Noone, A. B. Mariotto et al., and quot;Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, and " Cancer, vol. 120, no. 9, pp. 1290-1314, 2014.
9. J. L. Young Jr., S. D. Roffers, L. A. G. Ries et al., Eds., SEER Summary StagingManual-2000: Codes and Coding Instructions, National Cancer Institute, Bethesda, Md, USA, 2001.
10. S. B. Edge, D. R. Bryd, C. C. Compton et al., AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010.
11. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Breast schema for 1988 Based on AJCC, National Cancer Institute, Washington, DC, USA, 6th edition, 1988, http://seer.cancer.gov/seer.state/variables.seer/ajccstage/6th/breast.htm.
12. N. Breen, J. F. Gentleman, and J. S. Schiller, and quot;Update on mammography trends, and " Cancer, vol. 117, no. 10, pp. 2209-2218, 2011.
13. E. T. Warner, G. A. Colditz, J. R. Palmer, A. H. Partridge, B. A. Rosner, and R. M. Tamimi, and quot;Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40?" Breast Cancer Research and Treatment, vol. 142, no. 1, pp. 165-175, 2013.
14. K. G. Chee, D. V. Nguyen, M. Brown, D. R. Gandara, T. Wun, and P. N. Lara, and quot;Positron emission tomography and improved survival in patients with lung cancer: theWill Rogers phenomenon revisited, and " Archives of Internal Medicine, vol. 168, no. 14, pp. 1541-1549, 2008.
15. S. Mahner, S. Schirrmacher, W. Brenner et al., and quot;Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer, and " Annals of Oncology, vol. 19, no. 7, pp. 1249-1254, 2008.
16. N. Niikura, C. M. Costelloe, J. E. Madewell et al., and quot;FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer, and " Oncologist, vol. 16, no. 8, pp. 1111-1119, 2011.
17. A. M. Groves, M. Shastry, S. Ben-Haimet al., and quot;Defining the role of PET-CT in staging early breast cancer, and " Oncologist, vol. 17, no. 5, pp. 613-619, 2012.
18. C. M. Costelloe, E. M. Rohren, J. E. Madewell et al., and quot;Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis, and " The Lancet Oncology, vol. 10, no. 6, pp. 606-614, 2009.
19. D. Groheux, S. Giacchetti, M. Espié et al., and quot;The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study, and " Journal of Nuclear Medicine, vol. 52, no. 10, pp. 1526-1534, 2011.
20. R. L. Wahl, and quot;Current status of PET in breast cancer imaging, staging, and therapy, and " Seminars in Roentgenology, vol. 36, no. 3, pp. 250-260, 2001.
21. D. Wu and S. S. Gambhir, and quot;Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives, and " Clinical Breast Cancer, vol. 4, no. 1, pp. S55-S63, 2003.
22. R. W. Carlson and B. McCormick, and quot;Update: NCCN breast cancer clinical practice guidelines, and " Journal of the National Comprehensive CancerNetwork, vol. 3, supplement 1, pp. S7-S11, 2005.
23. D. Groheux, E. Hindié, M. Delord et al., and quot;Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer, and " Journal of the National Cancer Institute, vol. 104, no. 24, pp. 1879-1887, 2012.
24. L. E. Schnipper, T. J. Smith, D. Raghavan et al., and quot;American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology, and " Journal of Clinical Oncology, vol. 30, no. 14, pp. 1715-1724, 2012.
25. M. L. Crivello, K. Ruth, E. R. Sigurdson et al., and quot;Advanced imagingmodalities in early stage breast cancer: preoperative use in the United States Medicare population, and " Annals of Surgical Oncology, vol. 20, no. 1, pp. 102-110, 2013.
26. N. MdPaiman, S. A. MdAli, R. MdZinet al., and quot;Estrogen receptornegative breast ductal carcinoma: clinicopathological features and Mib-1 (Ki-67) proliferative index association, and " PLoS ONE, vol. 9, no. 2, Article IDe89172, 2014.
27. O. Pagani, K. N. Price, R. D. Gelber et al., and quot;Patternsof recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century, and " Breast Cancer Research and Treatment, vol. 117, no. 2, pp. 319-324, 2009.
28. W. F. Anderson, H. A. Katki, and P. S. Rosenberg, and quot;Incidence of breast cancer in the United States: current and future trends, and " Journal of theNationalCancer Institute, vol. 103, no. 18, pp. 1397-1402, 2011.
29. X. R. Yang, J. Chang-Clause, E. L. Goode et al., and quot;Associations of breast cancer risk factorswith tumor subtypes: a pooled analysis from the breast cancer association consortium studies, and " Journal of theNational Cancer Institute, vol. 103, no. 3, pp. 250-263, 2011.
30. N. Hou and D. Huo, and quot;Incidence rate of breast cancer in young women, and " JAMA-Journal of the American Medical Association, vol. 309, no. 23, p. 2433, 2013.
31. T. J. Mathews and B. E. Hamilton, and quot;Delayed childbearing: more women arehaving their first childlater in life, and quot;NCHSDataBrief 21, 2009.
32. Y. Y. Lee, C. L. Roberts, T. Dobbins et al., and quot;Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study, and " BJOG, vol. 119, no. 13, pp. 1572-1582, 2012.
33. S. K. Pal, M. Dehaven, R. A. Nelson et al., and quot;Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer, and " BMC Cancer, vol. 12, article 435, 2012.